Randomized Clinical Trial (RCT) to test the effectiveness of a new innovation support model
How to cite
Romero, Mario; Ataz, Rafael; Lopez, Francisco Javier. 2021. "Randomized Clinical Trial (RCT) to test the effectiveness of a new innovation support model." AEA RCT Registry. AEARCTR-0008309. https://doi.org/10.1257/rct.8309-1.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
The Trial aims at developing a RCT to compare the socio-economic impact produced in the SMEs that choose to innovate based on a previously identified challenges with economic support against those that innovate based on a previously identified challenges with economic support and guided by the tutelage of (co-creation) and supported by INFO with “go to market” services. The main goal is to analyse the performance and the advantages and constraints for INFO of one or the other model.
Additionally, other interesting issues can be addressed in the RCT:
•Commitment to business digitisation to get out of the Covid19 crisis
•To satisfy technological needs of large-tractor companies located in the Region of Murcia through the competition of SMEs acting as providers of technological solutions. (such a target of companies being traditionally excluded for ERDF intervention in the Murcia region)
The main outcome of the project will be provided at the end of the project, with the analysis of the Key Performance Indicators (KPIs) that will permit the comparison between the SMEs following the both technical arms defined in the project (i.e. Co-creation and business support) or without these added value services.
All the SMEs involved in the project, belonging to control arm or intervention arm will receive the same funding rate to carry out their projects and the same challenge fiche. The only difference will be the added value services that will join the intervention group companies according to the inDemand model (ie. co-creation + business support).
It is a Controlled Randomized Clinical Trial, stratified, non blinded, unicentric and with two parallel branches to study, based on the innovation support model (inDemand Model with co-creation and business support versus inDemand Model without additional support).
Intervention
First the recruitment of the SMEs will be carried out by INFO. This is a very important aspect in the RCT, in order to ensure that the sample size is high enough to ensure the validity of the project results. INFO will use all the databases and resources to identify the highest number of potential SMEs. Initially, it is expected that around 40 SMEs will be involved in the project. There will be the same number of companies in both arms. In order to get the highest number of SMEs and increase as much as possible the sample size, the SMEs to be allocated can be placed not only in the Murcia region but also out of the region. This was not foreseen in the initial version of DoA and will permit us to select the best companies and to obtain a better sample size.
The budget limit and current situation with respect to the Covid19 pandemic could make more difficult the participation of SMEs. INFO in a close cooperation with the Large-tractor companies will work to encourage the SMEs involvement.
There will be launched a single call with Innosup-6 budget for SMEs that will apply to provide services to necessities in the fields of innovation, digitisation and response to Covid19 identified by large-tractor companies in the Murcia region. The call results will be classified and the selected projects will be contacted.
The randomization process will be implemented at this point, distributing the SMEs in both arms (intervention and control) and will receive the funding with or without Co-creation and Business Support services. SMEs will carry out their projects according with the inDemand approach, with pre-identified challenges promoted by the Large Companies. Half of the SMEs will execute their projects without additional support, and the other will have access to Co-creation process with the Large Company and will receive a Business support service, helping the SMEs in aspects like internationalization, IPR issues, etc. More details of these aspects are included in the Annex II. Depending of the nature of the projects presented by the SMEs and the necessities that they could have, it will be selected the option that will be applied to each SME, Co-creation or Business support.
At the end of the project, we would compare the results of these companies with inDemand support (co-creation + business support) versus mere investigation of SMEs without that support. Previously, an identification of challenges of large-tractor companies would be carried out and later a single call: challenges without support versus challenges with support. To achieve this, a set of Key Performance Indicators (see point 5) have been identified, concerning aspects like innovation improvement, economic impact, and etcetera.
Experimental design
Controlled clinical trial, stratified randomized (by sectors), non blinded, unicentric and with two parallel branches to study, based on the innovation support model developed by the company (INDEMAND Model versus traditional model).
This study design ensures homogenization in the characteristics of the companies that will be included in both groups. The randomization ensures that the characteristics of the companies of the traditional branch are very similar to the characteristics of the companies of the INDEMAND branch and we will ensure that the differences obtained at the end of the process will be mostly caused by the model used to finance research in innovation.
In principle, this confers great internal validity to the study. In addition, companies may compete with several research projects but always in the same branch of the study.
Design details
Cited by
No citation data available for this registration yet.